Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on August 16, 2016. The report details the final analysis results of the Phase 3 AFFINITY trial for the drug custirsen in metastatic castrate-resistant prostate cancer (CRPC) and outlines subsequent strategic actions.
Key Financial Metrics
This filing is a Current Report regarding specific events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
- AFFINITY Trial Failure: The Phase 3 trial of custirsen in CRPC patients failed to meet its primary endpoint of demonstrating a statistically significant improvement in overall survival when combined with cabazitaxel/prednisone versus cabazitaxel/prednisone alone.
- Survival Data: Median overall survival was 14.2 months for the custirsen arm versus 13.4 months for the control arm, with a hazard ratio of 0.946.
- Safety Profile: Safety data remained consistent with previous trials of custirsen in CRPC.
Outlook, Management Commentary, and Strategic Actions
- ENSPIRIT Trial Strategy: The Company plans to discuss an early analysis of the Phase 3 ENSPIRIT trial (custirsen in non-small cell lung cancer) with the FDA. The trial is over 90% enrolled with more than 80% of events occurred.
- Statistical Parameters: The proposed early analysis will maintain the hypothesized hazard ratio of 0.75 and the p-value for the final survival analysis, with a minimal reduction in power and a slight change in the critical hazard ratio from 0.84 to 0.83.
- Strategic Alternatives: The Company has engaged MTS Health Partners, LP as an advisor to explore strategic alternatives.
Investor Verification Checklist
- Verify the specific terms of the proposed early analysis agreement with the FDA for the ENSPIRIT trial.
- Monitor the progress and outcome of the strategic alternatives process led by MTS Health Partners, LP.
- Review the Company's cash runway and liquidity position in subsequent filings (e.g., 10-Q or 10-K) given the lack of revenue-generating assets from the failed AFFINITY trial.
- Confirm the timeline for the final readout of the ENSPIRIT trial.